Tumor digital twins uncover therapeutic strategies in triple-negative breast cancer.

A TNBC digital twin framework predicts treatment responses and links mutational and transcriptional biomarkers to clinical outcome in PARTNER, a randomized trial of platinum chemotherapy ± PARP inhibitors.

• Why it matters: Triple-negative breast cancer has limited options and frequent relapse, creating a need for personalized strategies that account for each tumor’s biology, clonal makeup, and evolution.
• What they did: The study builds a mechanistic qualitative gene/protein network digital twin, parameterized with patient-specific molecular data, then validates it against PARTNER clinical outcomes for platinum-based chemotherapy with or without PARP inhibitors.
• The result: The model accurately predicts responses and identifies mutational and transcriptional biomarkers associated with clinical outcome, offering an interpretable alternative to black-box predictors for precision oncology.

AI summary of the abstract · may contain errors · not medical advice · read the paper.